Cellnovo gets early foothold in US diabetes market with TypeZero partnership
This article was originally published in Clinica
Executive Summary
Cellnovo will see its diabetes management system, said to be the first and only of its kind to have an insulin patch pump with mobile connectivity features, trialed in a $12.7m international artificial pancreas study after forging a partnership with TypeZero Technologies, a US start-up spun out from the University of Virginia.